Literature DB >> 25536022

Herbal medicine for low-back pain.

Hanna Oltean1, Chris Robbins, Maurits W van Tulder, Brian M Berman, Claire Bombardier, Joel J Gagnier.   

Abstract

BACKGROUND: Low-back pain (LBP) is a common condition and imposes a substantial economic burden upon people living in industrialized societies. A large proportion of people with chronic LBP use complementary and alternative medicine (CAM), visit CAM practitioners, or both. Several herbal medicines have been purported for use in treating people with LBP. This is an update of a Cochrane Review first published in 2006.
OBJECTIVES: To determine the effectiveness of herbal medicine for non-specific LBP. SEARCH
METHODS: We searched the following electronic databases up to September 2014: MEDLINE, EMBASE, CENTRAL, CINAHL, Clinical Trials.gov, World Health Organization International Clinical Trials Registry Portal and PubMed; checked reference lists in review articles, guidelines and retrieved trials; and personally contacted individuals with expertise in this area. SELECTION CRITERIA: We included randomized controlled trials (RCTs) examining adults (over 18 years of age) suffering from acute, sub-acute, or chronic non-specific LBP. The interventions were herbal medicines which we defined as plants used for medicinal purposes in any form. Primary outcome measures were pain and function. DATA COLLECTION AND ANALYSIS: A library scientist with the Cochrane Back Review Group conducted the database searches. One review author contacted content experts and acquired relevant citations. We downloaded full references and abstracts of the identified studies and retrieved a hard copy of each study for final inclusion decisions. Two review authors assessed risk of bias, GRADE criteria (GRADE 2004), and CONSORT compliance and a random subset were compared to assessments by a third individual. Two review authors assessed clinical relevance and resolved any disagreements by consensus. MAIN
RESULTS: We included 14 RCTs (2050 participants) in this review. One trial on Solidago chilensis M. (Brazilian arnica) (20 participants) found very low quality evidence of reduction in perception of pain and improved flexibility with application of Brazilian arnica-containing gel twice daily as compared to placebo gel. Capsicum frutescens cream or plaster probably produces more favourable results than placebo in people with chronic LBP (three trials, 755 participants, moderate quality evidence). Based on current evidence, it is not clear whether topical capsicum cream is more beneficial for treating people with acute LBP compared to placebo (one trial, 40 participants, low quality evidence). Another trial found equivalence of C. frutescens cream to a homeopathic ointment (one trial, 161 participants, very low quality evidence). Daily doses of Harpagophytum procumbens (devil's claw), standardized to 50 mg or 100 mg harpagoside, may be better than placebo for short-term improvements in pain and may reduce use of rescue medication (two trials, 315 participants, low quality evidence). Another H. procumbens trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (Vioxx®) but was of very low quality (one trial, 88 participants, very low quality). Daily doses of Salix alba (white willow bark), standardized to 120 mg or 240 mg salicin, are probably better than placebo for short-term improvements in pain and rescue medication (two trials, 261 participants, moderate quality evidence). An additional trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (one trial, 228 participants) but was graded as very low quality evidence. S. alba minimally affected platelet thrombosis versus a cardioprotective dose of acetylsalicylate (one trial, 51 participants). One trial (120 participants) examining Symphytum officinale L. (comfrey root extract) found low quality evidence that a Kytta-Salbe comfrey extract ointment is better than placebo ointment for short-term improvements in pain as assessed by VAS. Aromatic lavender essential oil applied by acupressure may reduce subjective pain intensity and improve lateral spine flexion and walking time compared to untreated participants (one trial, 61 participants,very low quality evidence). No significant adverse events were noted within the included trials. AUTHORS'
CONCLUSIONS: C. frutescens (Cayenne) reduces pain more than placebo. Although H. procumbens, S. alba, S. officinale L., S. chilensis, and lavender essential oil also seem to reduce pain more than placebo, evidence for these substances was of moderate quality at best. Additional well-designed large trials are needed to test these herbal medicines against standard treatments. In general, the completeness of reporting in these trials was poor. Trialists should refer to the CONSORT statement extension for reporting trials of herbal medicine interventions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25536022      PMCID: PMC7197042          DOI: 10.1002/14651858.CD004504.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  74 in total

1.  Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain.

Authors:  S Chrubasik; T Weiser; B Beime
Journal:  Phytother Res       Date:  2010-12       Impact factor: 5.878

2.  Diagnostic testing and treatment of low back pain in United States emergency departments: a national perspective.

Authors:  Benjamin W Friedman; Mikaela Chilstrom; Polly E Bijur; E John Gallagher
Journal:  Spine (Phila Pa 1976)       Date:  2010-11-15       Impact factor: 3.468

3.  [Shoulder back lumbar pain treated with application with argy wormwood feeleaf volatile oil].

Authors:  Wan-Ning Liu; Hong-Ren Gan; Cun-Zhong Fang
Journal:  Zhongguo Zhen Jiu       Date:  2013-02

4.  Efficacy and tolerance of Harpagophytum extract LI 174 in patients with chronic non-radicular back pain.

Authors:  D Laudahn; A Walper
Journal:  Phytother Res       Date:  2001-11       Impact factor: 5.878

5.  [Effects of Harpagophytum procumbens LI 174 (devil's claw) on sensory, motor und vascular muscle reagibility in the treatment of unspecific back pain].

Authors:  H Göbel; A Heinze; M Ingwersen; U Niederberger; D Gerber
Journal:  Schmerz       Date:  2001-02       Impact factor: 1.107

6.  Low back pain: a twentieth century health care enigma.

Authors:  G Waddell
Journal:  Spine (Phila Pa 1976)       Date:  1996-12-15       Impact factor: 3.468

7.  A 1-year follow-up after a pilot study with Doloteffin for low back pain.

Authors:  S Chrubasik; O Künzel; J Thanner; C Conradt; A Black
Journal:  Phytomedicine       Date:  2005-01       Impact factor: 5.340

8.  Use of complementary and alternative medicine by those with a chronic disease and the general population--results of a national population based survey.

Authors:  Amy Metcalfe; Jeanne Williams; Jane McChesney; Scott B Patten; Nathalie Jetté
Journal:  BMC Complement Altern Med       Date:  2010-10-18       Impact factor: 3.659

9.  Patient-perceived benefit during one year of treatment with Doloteffin.

Authors:  S Chrubasik; C Chrubasik; O Künzel; A Black
Journal:  Phytomedicine       Date:  2007-05-22       Impact factor: 5.340

10.  Efficacy and safety of comfrey root extract ointment in the treatment of acute upper or lower back pain: results of a double-blind, randomised, placebo controlled, multicentre trial.

Authors:  B M Giannetti; C Staiger; M Bulitta; H-G Predel
Journal:  Br J Sports Med       Date:  2009-05-21       Impact factor: 13.800

View more
  17 in total

Review 1.  Obstacles to the Prescription and Use of Opioids.

Authors:  Rachel S Wallwork; Fallon E Chipidza; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2016-02-18

Review 2.  Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews.

Authors:  Sheena Derry; Philip J Wiffen; Eija A Kalso; Rae F Bell; Dominic Aldington; Tudor Phillips; Helen Gaskell; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-05-12

Review 3.  Non-Specific Low Back Pain.

Authors:  Jean-François Chenot; Bernhard Greitemann; Bernd Kladny; Frank Petzke; Michael Pfingsten; Susanne Gabriele Schorr
Journal:  Dtsch Arztebl Int       Date:  2017-12-25       Impact factor: 5.594

Review 4.  Complementary and alternative medicine therapies for chronic pain.

Authors:  Brent A Bauer; Jon C Tilburt; Amit Sood; Guang-Xi Li; Shi-Han Wang
Journal:  Chin J Integr Med       Date:  2016-05-26       Impact factor: 1.978

Review 5.  Role of Alternative Therapies for Chronic Pain Syndromes.

Authors:  Donna-Ann Thomas; Benjamin Maslin; Aron Legler; Erin Springer; Abbas Asgerally; Nalini Vadivelu
Journal:  Curr Pain Headache Rep       Date:  2016-05

6.  Herbal medicinal products or preparations for neuropathic pain.

Authors:  Adele Boyd; Chris Bleakley; Deirdre A Hurley; Chris Gill; Mary Hannon-Fletcher; Pamela Bell; Suzanne McDonough
Journal:  Cochrane Database Syst Rev       Date:  2019-04-02

7.  Tibetan herbal pain-relieving plaster for low back pain: A systematic review and meta-analysis.

Authors:  Mingxiao Yang; Susan Q Li; Colleen M Smith; Yi Lily Zhang; Ting Bao; Jun J Mao
Journal:  Biomed Pharmacother       Date:  2021-05-18       Impact factor: 7.419

8.  A Pilot Study on Bioactive Constituents and Analgesic Effects of MyrLiq®, a Commiphora myrrha Extract with a High Furanodiene Content.

Authors:  Antonio Germano; Andrea Occhipinti; Francesca Barbero; Massimo E Maffei
Journal:  Biomed Res Int       Date:  2017-05-24       Impact factor: 3.411

9.  Effectiveness and safety of moxibustion treatment for non-specific lower back pain: protocol for a systematic review.

Authors:  Jungtae Leem; Seunghoon Lee; Yeoncheol Park; Byung-Kwan Seo; Yeeun Cho; Jung Won Kang; Yoon Jae Lee; In-Hyuk Ha; Hyun-Jong Lee; Eun-Jung Kim; Sanghoon Lee; Dongwoo Nam
Journal:  BMJ Open       Date:  2017-06-23       Impact factor: 2.692

10.  Wound healing potential of lavender oil by acceleration of granulation and wound contraction through induction of TGF-β in a rat model.

Authors:  Hiroko-Miyuki Mori; Hiroshi Kawanami; Hirohisa Kawahata; Motokuni Aoki
Journal:  BMC Complement Altern Med       Date:  2016-05-26       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.